Acute myocardial infarction (AMI) remains a leading cause of morbidity and mortality worldwide, primarily resulting from an abrupt coronary artery occlusion that deprives myocardial tissue of oxygen.

N-terminal pro B-type peptide (NT-proBNP) has been associated with risk of myocardial infarction (MI), but less is known about the relationship between NT-proBNP and very small non ST-elevation MI, ...

Clinical auditing reveals significant misclassification in administrative codes for myocardial infarction (MI), with only 39% of type 1 (T1MI) codes and 72% of type 2 (T2MI) codes for the condition ...

The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, ...

HealthDay News — For patients with type 2 diabetes, the risk of acute myocardial infarction (AMI) is not significantly different for long-acting insulin analogs versus other basal insulin therapies, ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Denmark: A study published in Cardiovascular Diabetology has found that patients with overweight or obesity who have prediabetes after a myocardial infarction face a substantially higher risk ...